Gilead and Carna Bio announce R&D collaboration to develop immuno-oncology therapies
Gilead Sciences and Carna Biosciences announced the companies have entered into a research and development collaboration to develop and commercialize small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform. June 24, 2019